These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28266734)

  • 1. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.
    Avula S; Nguyen TM; Marble M; Lilje C
    Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of severe cardiomyopathy in infantile Pompe disease.
    Parent JJ; Schamberger M
    Cardiol Young; 2015 Jan; 25(1):146-8. PubMed ID: 25544546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antenatal diagnosis of pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy.
    Hamdan MA; El-Zoabi BA; Begam MA; Mirghani HM; Almalik MH
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S333-9. PubMed ID: 20821053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 5. [Enzyme replacement therapy in a boy with infantile Pompe disease: cardiac follow-up].
    Bonnefoy R; Labarthe F; Paoli F; Chantreuil J; Barthez MA; Froissart R; Poinsot J; Chantepie A
    Arch Pediatr; 2008 Dec; 15(12):1760-4. PubMed ID: 18995995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.
    van Capelle CI; Poelman E; Frohn-Mulder IM; Koopman LP; van den Hout JMP; Régal L; Cools B; Helbing WA; van der Ploeg AT
    Int J Cardiol; 2018 Oct; 269():104-110. PubMed ID: 30049495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
    Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
    Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease.
    Scheffers LE; Kok R; van den Berg LE; van den Hout JMP; Boersma E; van Capelle CI; Helbing WA; van der Ploeg AT; Koopman LP
    Int J Cardiol; 2023 Jun; 380():65-71. PubMed ID: 36893858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy.
    Chen CA; Chien YH; Hwu WL; Lee NC; Wang JK; Chen LR; Lu CW; Lin MT; Chiu SN; Chiu HH; Wu MH
    J Card Fail; 2011 Nov; 17(11):930-6. PubMed ID: 22041330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
    Hamdan MA; Almalik MH; Mirghani HM
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation.
    But WM; Lee SH; Chan AO; Lau GT
    Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy in an infant with Pompe's disease with severe cardiomyopathy.
    Tanzer F; Buyukkayhan D; Cansu Mutlu E; Kalender Korkmaz F
    J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1159-62. PubMed ID: 20333876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
    Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
    Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infantile-onset pompe disease: a tale of two cases.
    Tolani D; Bansal N; Sehgal S
    Cardiol Young; 2020 Feb; 30(2):275-277. PubMed ID: 31983366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease.
    Kenney-Jung D; Korlimarla A; Spiridigliozzi GA; Wiggins W; Malinzak M; Nichting G; Jung SH; Sun A; Wang RY; Al Shamsi A; Phornphutkul C; Owens J; Provenzale JM; Kishnani PS
    Mol Genet Metab; 2024 Feb; 141(2):108119. PubMed ID: 38184429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variability in the clinical presentation of Pompe disease in infancy: two case reports and response to treatment with human recombinant enzyme].
    Moreno-Medinilla E; Berzosa-López R; Mora-Ramírez MD; Blasco-Alonso J; Martínez-Antón J
    Rev Neurol; 2014 Dec; 59(11):503-7. PubMed ID: 25418145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Variability in the clinical presentation of Pompe disease: development following enzyme replacement therapy].
    Ley-Martos M; Salado-Reyes MJ; Espinosa-Rosso R; Solera-García J; Jiménez-Jiménez L
    Rev Neurol; 2015 Nov; 61(9):416-20. PubMed ID: 26503317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.